Complementopathies and precision medicine

J Clin Invest. 2020 May 1;130(5):2152-2163. doi: 10.1172/JCI136094.

Abstract

The renaissance of complement diagnostics and therapeutics has introduced precision medicine into a widened field of complement-mediated diseases. In particular, complement-mediated diseases (or complementopathies) with ongoing or published clinical trials of complement inhibitors include paroxysmal nocturnal hemoglobinuria, cold agglutinin disease, hemolytic uremic syndrome, nephropathies, HELLP syndrome, transplant-associated thrombotic microangiopathy, antiphospholipid antibody syndrome, myasthenia gravis, and neuromyelitis optica. Recognizing that this field is rapidly expanding, we aim to provide a state-of-the-art review of (a) current understanding of complement biology for the clinician, (b) novel insights into complement with potential applicability to clinical practice, (c) complement in disease across various disciplines (hematology, nephrology, obstetrics, transplantation, rheumatology, and neurology), and (d) the potential future of precision medicine. Better understanding of complement diagnostics and therapeutics will not only facilitate physicians treating patients in clinical practice but also provide the basis for future research toward precision medicine in this field.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Anemia, Hemolytic* / blood
  • Anemia, Hemolytic* / pathology
  • Anemia, Hemolytic* / therapy
  • Complement System Proteins / metabolism*
  • Humans
  • Precision Medicine*
  • Thrombotic Microangiopathies* / blood
  • Thrombotic Microangiopathies* / pathology
  • Thrombotic Microangiopathies* / therapy

Substances

  • Complement System Proteins